Blood tau fragment may flag CTE in living former football players
A small case series links higher blood eMTBR-tau to autopsy-confirmed CTE in 21 former football players, a step toward diagnosing CTE during life.
Summary
Chronic traumatic encephalopathy (CTE), a brain disease tied to repeated head impacts, can only be confirmed at autopsy today. A small study in 21 former American football players who donated their brains found that blood levels of a tau fragment called eMTBR-tau were higher in those with CTE than in those without (β=1.61, 95% CI 0.51-2.70). Levels were highest in players who also had Alzheimer's pathology and intermediate in high-stage CTE without Alzheimer's changes. Another biomarker, p-tau217, was mostly negative or intermediate in CTE unless Alzheimer's disease was also present. A separate Washington University case-control study found a related measure, plasma eMTBR-tau243, elevated in late-stage CTE. The work is preliminary: the sample is small, it is a case series, and it has not been validated for diagnosing individuals. If confirmed, such a test could support research trials and earlier diagnosis.
Detailed Summary
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease linked to repetitive head impacts in contact sports. It can currently be diagnosed only at autopsy, which makes it hard to study, to distinguish from other causes of cognitive and behavioral change, or to test treatments for in living people.
In a case series of 21 former American football players who had donated their brains, researchers measured blood levels of endogenously cleaved microtubule-binding region tau (eMTBR-tau), a fragment tied to tau tangle pathology. Levels were higher in CTE-positive than CTE-negative participants (β=1.61, 95% CI 0.51-2.70). They were highest in players who also had Alzheimer's pathology at autopsy, intermediate in high-stage CTE without Alzheimer's pathology, and higher in high-stage CTE than in low-stage or no CTE. Phosphorylated tau 217 (p-tau217) was negative or intermediate in CTE cases except in athletes with comorbid Alzheimer's disease. The study was presented at the CTAD conference and published in JAMA.
The result echoes a Washington University in St. Louis case-control study, also in JAMA, in which plasma eMTBR-tau243, measured by mass spectrometry, was elevated in late-stage CTE and some other tauopathies. The presenter noted that the immunoassay and mass-spectrometry measures capture the same biology and correlate strongly. eMTBR-tau243 has also emerged as an Alzheimer's biomarker, with a 2025 study linking it more strongly to tangle pathology than other markers.
If validated, a blood test could improve selection of participants for research, support clinicopathological studies, and help evaluate preventive and therapeutic interventions. Editorialists noted it could help separate traumatic encephalopathy syndrome from other causes of symptoms, especially with Alzheimer's copathology.
The caveats are substantial. The sample is tiny, the participants were brain donors who may not represent all players, and the researchers themselves call this the discovery phase. The test has not been shown to diagnose CTE in an individual, and elevated levels also occur in Alzheimer's and other tauopathies, so specificity remains an open question. Larger independent studies are needed.
Key Findings
- In 21 autopsied former football players, blood eMTBR-tau was higher in CTE-positive than CTE-negative cases (β=1.61, 95% CI 0.51-2.70).
- eMTBR-tau was highest with comorbid Alzheimer's pathology and intermediate in high-stage CTE alone; high-stage exceeded low-stage or no CTE.
- p-tau217 was negative or intermediate in CTE, elevated mainly when Alzheimer's disease was also present, suggesting some separation from Alzheimer's.
- A separate Washington University case-control study found plasma eMTBR-tau243 elevated in late-stage CTE and some other tauopathies.
Methodology
This is a news report on a small case series (n=21 brain donors, former American football players) presented at CTAD and published in JAMA, with an accompanying JAMA editorial. Biomarker levels were compared with autopsy-confirmed neuropathology, a strong reference standard. The article reports no accuracy figures such as sensitivity or specificity.
Study Limitations
The sample is small and drawn from brain donors, so selection bias is likely, and no diagnostic accuracy was reported. Specificity versus Alzheimer's and other tauopathies, and performance at early stages, are unproven. Check the JAMA papers for the assay details, confidence intervals and replication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
